Poor
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims concern exclusivity, patents, and external trackers not present in the provided prescribing information. All extracted claims are not supported by the supplied label content (absent_from_label), indicating substantial misalignment.
Category Scores
Accurate Statements
Unsupported Statements
Humalog’s “loss of exclusivity” in Europe depends on which legal protection ended first for the specific product presentation (strength/formulation) and the relevant country.
Not supported by the supplied prescribing information; labeling does not discuss exclusivity timelines.
Exclusivity can include multiple layers such as patents, supplementary protection certificates (SPCs), and, in some cases, data exclusivity tied to marketing authorization.
Not supported by the supplied prescribing information; labeling does not describe IP/exclusivity mechanisms.
DrugPatentWatch tracks patent and exclusivity status by country and dates, including when specific patents or related protections are expected to end.
Not supported by the supplied prescribing information; external tracking tool usage is not described in labeling.
DrugPatentWatch tracks when specific patents or related protections are expected to end.
Not supported by the supplied prescribing information; labeling does not reference external patent trackers.
You can use it to pinpoint the European timing for the protection that is expiring for the Humalog filing you mean.
Not supported by the supplied prescribing information; labeling does not reference external patent/exclusivity records.
European “loss of exclusivity” is not always a single EU-wide date in practice.
Not supported by the supplied prescribing information; labeling does not discuss exclusivity timelines by region.
Exact timing can vary by country.
Not supported by the supplied prescribing information; labeling does not provide variability of exclusivity timing by country.
Exact timing can vary by product form.
Not supported by the supplied prescribing information; labeling does not break down exclusivity timing by product form.
Exact timing can vary by whether the relevant expiry is a patent or an SPC tied to a marketing authorization.
Not supported by the supplied prescribing information; labeling does not differentiate exclusivity expiry types.
If you tell me the specific country (or whether you mean EU generally) and which Humalog product, I can help you interpret the most relevant “exclusivity ended” date for that market and presentation using the cited patent/exclusivity record.
Not supported by the supplied prescribing information; labeling does not contain guidance on external patent/exclusivity interpretation.
End of patent/SPC protection (first generic/biosimilar entry pathway opens).
Not supported by the supplied prescribing information; labeling does not provide end dates for patents/SPCs.
End of regulatory data protection (may affect approvals).
Not supported by the supplied prescribing information; regulatory data protection timelines are not described in labeling.
End of marketing exclusivity tied to the approval process.
Not supported by the supplied prescribing information; such exclusivity details are not part of labeling.
If you confirm which meaning you need, the date you’re looking for should be much easier to identify.
Not supported by the supplied prescribing information; this is a convenience statement about external records, not labeling.
Contradictions
Important Omissions
No safety-related content (contraindications, boxed warnings, dosing safety, pregnancy, pediatric safety) is addressed by the claims; safety-oriented omissions relative to labeling exist but are not evaluated in the claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims evaluated concern exclusivity and do not present safety information to assess against the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Exclusivity-related claims are not supported by the provided prescribing information.
Suggested Improvement
Limit claims to label-approved content (indications, dosing, safety, administration, and monitoring) and avoid external-tracker references unless explicitly supported by the label.